Johnson & Johnson Shares Rise 53% Over Past Year Amid Analyst Upgrades
Johnson & Johnson shares have climbed 53% over the past year and 15% year-to-date, with RBC Capital and Bank of America raising price targets on the stock amid strong financial performance and 6% revenue growth in 2025.
Johnson & Johnson (NYSE:JNJ) shares are up by 53% over the past year and by 15% year-to-date. The pharmaceutical company's full-year revenue in 2025 grew by 6% to $94.2 billion, while the firm outlined that revenue could sit at $100.5 billion in 2026.
RBC Capital raised Johnson & Johnson's share price target to $255 from $240 and kept an Outperform rating on the shares. The bank pointed out that the pharmaceutical company had strong finances to navigate its legal woes.
Bank of America also raised Johnson & Johnson's share price target, bumping the target to $227 from $221 and keeping a Neutral rating on the stock. According to the firm, the company's organic growth was leading to healthier multiples.
Some factors that have driven optimism about the company include Johnson & Johnson's cancer drug portfolio and its orthopedic spinoff.